Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors.

Nuclear receptor (NR) ligands occupy a pocket that lies within the core of the NR ligand-binding domain (LBD), and most NR LBDs lack obvious entry/exit routes upon the protein surface. Thus, significant NR conformational rearrangements must accompany ligand binding and release. The precise nature of these processes, however, remains poorly understood. Here, we utilize locally enhanced sampling (LES) molecular dynamics computer simulations to predict molecular motions of x-ray structures of thyroid hormone receptor (TR) LBDs and determine events that permit ligand escape. We find that the natural ligand 3,5,3'-triiodo-L-thyronine (T(3)) dissociates from the TRalpha1 LBD along three competing pathways generated through i), opening of helix (H) 12; ii), separation of H8 and H11 and the Omega-loop between H2 and H3; and iii), opening of H2 and H3, and the intervening beta-strand. Similar pathways are involved in dissociation of T(3) and the TRbeta-selective ligand GC24 from TRbeta; the TR agonist IH5 from the alpha- and beta-TR forms; and Triac from two natural human TRbeta mutants, A317T and A234T, but are detected with different frequencies in simulations performed with the different structures. Path I was previously suggested to represent a major pathway for NR ligand dissociation. We propose here that Paths II and III are also likely ligand escape routes for TRs and other NRs. We also propose that different escape paths are preferred in different situations, implying that it will be possible to design NR ligands that only associate stably with their cognate receptors in specific cellular contexts.

[1]  Q. Gibson,et al.  Mapping the Pathways for O2 Entry Into and Exit from Myoglobin* , 2001, The Journal of Biological Chemistry.

[2]  Thomas S. Scanlan,et al.  Design of thyroid hormone receptor antagonists from first principles , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  K. Schulten,et al.  Unbinding of retinoic acid from its receptor studied by steered molecular dynamics. , 1999, Biophysical journal.

[4]  Johan Auwerx,et al.  Nuclear receptors and the control of metabolism. , 2003, Annual review of physiology.

[5]  M. Brunori,et al.  Cavities and packing defects in the structural dynamics of myoglobin , 2001, EMBO reports.

[6]  R. Fletterick,et al.  Two RTH Mutants with Impaired Hormone Binding , 2003 .

[7]  Peter A. Kollman,et al.  Molecular mechanics simulation of protein-ligand interactions: binding of thyroid hormone analogs to prealbumin , 1982 .

[8]  R G Smith,et al.  Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.

[9]  D. Moore,et al.  Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. , 2000, Molecular cell.

[10]  Paul Webb,et al.  Thyroxine-Thyroid Hormone Receptor Interactions* , 2004, Journal of Biological Chemistry.

[11]  B. Katzenellenbogen,et al.  Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.

[12]  K. O'reilly,et al.  A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. , 2001, Journal of the American Chemical Society.

[13]  Paul Webb,et al.  Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight , 2004, Trends in Endocrinology & Metabolism.

[14]  R Elber,et al.  Distal pocket residues affect picosecond ligand recombination in myoglobin. An experimental and molecular dynamics study of position 29 mutants. , 1992, The Journal of biological chemistry.

[15]  R J Fletterick,et al.  Nuclear-receptor ligands and ligand-binding domains. , 1999, Annual review of biochemistry.

[16]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[17]  R. Fletterick,et al.  Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.

[18]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[19]  R. Fletterick,et al.  Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the N-terminal ligand-binding domain. , 2003, Molecular endocrinology.

[20]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[21]  J. Katzenellenbogen,et al.  Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. , 2001, Molecular endocrinology.

[22]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[23]  J. Baxter,et al.  Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. , 2004, Endocrinology.

[24]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[25]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[26]  Michael L. Quillin,et al.  Structural and functional effects of apolar mutations of the distal valine in myoglobin. , 1995, Journal of molecular biology.

[27]  P. Chambon,et al.  Crystal structure of the human RXRα ligand‐binding domain bound to its natural ligand: 9‐cis retinoic acid , 2000 .

[28]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[29]  P. Kraulis A program to produce both detailed and schematic plots of protein structures , 1991 .

[30]  Koh Jt,et al.  A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. , 2001 .

[31]  K. Schulten,et al.  Energetics of glycerol conduction through aquaglyceroporin GlpF , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Kendall W Nettles,et al.  Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.

[33]  J D Baxter,et al.  The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.

[34]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[35]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[36]  J. Fetrow Omega loops; nonregular secondary structures significant in protein function and stability , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  R. Fletterick,et al.  MOLECULAR AND STRUCTURAL BIOLOGY OF THYROID HORMONE RECEPTORS , 1998, Clinical and experimental pharmacology & physiology. Supplement.

[38]  M. Karplus,et al.  Enhanced sampling in molecular dynamics: use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin , 1990 .

[39]  Paul Webb,et al.  Selective modulation of thyroid hormone receptor action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[40]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[41]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[42]  P. Chambon,et al.  Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. , 2000, The EMBO journal.

[43]  Grazia Chiellini,et al.  Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[45]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[46]  P. Webb Selective activators of thyroid hormone receptors , 2004, Expert opinion on investigational drugs.

[47]  L. Ye,et al.  Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. , 2003, Journal of medicinal chemistry.

[48]  R. Elber,et al.  Application of the locally enhanced sampling (LES) and a mean field with a binary collision correction (cLES) to the simulation of Ar diffusion and NO recombination in myoglobin , 1994 .

[49]  J. Baxter,et al.  Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. , 2002, Journal of medicinal chemistry.

[50]  John E. Straub,et al.  ENERGY EQUIPARTITIONING IN THE CLASSICAL TIME-DEPENDENT HARTREE APPROXIMATION , 1991 .

[51]  K E Carlson,et al.  Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. , 1997, Biochemistry.

[52]  Jorge Nocedal,et al.  On the limited memory BFGS method for large scale optimization , 1989, Math. Program..

[53]  J. Schwabe,et al.  A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.

[54]  L. Moore,et al.  2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. , 2003, Biochemistry.

[55]  L. Verlet Computer "Experiments" on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones Molecules , 1967 .

[56]  M Karplus,et al.  Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. , 1999, Journal of molecular biology.

[57]  R J Fletterick,et al.  Hormone selectivity in thyroid hormone receptors. , 2001, Molecular endocrinology.

[58]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[59]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[60]  L. Martínez,et al.  A review on the dynamics of water , 2004 .

[61]  R. Fletterick,et al.  Two resistance to thyroid hormone mutants with impaired hormone binding. , 2003, Molecular endocrinology.

[62]  Johan Malm,et al.  Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[64]  Ron Elber,et al.  The thermal equilibrium aspects of the time dependent Hartree and the locally enhanced sampling approximations: Formal properties, a correction, and computational examples for rare gas clusters , 1993 .

[65]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Y. Uratani Immunoaffinity purification and reconstitution of sodium-coupled branched-chain amino acid carrier of Pseudomonas aeruginosa. , 1992, The Journal of biological chemistry.